stoxline Quote Chart Rank Option Currency Glossary
Glaukos Corporation (GKOS)
108.89  1.45 (1.35%)    05-24 16:00
Open: 108.09
High: 109.6225
Volume: 391,084
Pre. Close: 107.44
Low: 107.28
Market Cap: 5,485(M)
Technical analysis
2024-05-27 4:46:11 PM
Short term     
Mid term     
Targets 6-month :  133.11 1-year :  155.48
Resists First :  113.97 Second :  133.11
Pivot price 108.71
Supports First :  102.48 Second :  95.38
MAs MA(5) :  108.37 MA(20) :  106.72
MA(100) :  94.57 MA(250) :  80.2
MACD MACD :  2.7 Signal :  3.2
%K %D K(14,3) :  54.2 D(3) :  61.4
RSI RSI(14): 60.4
52-week High :  113.97 Low :  54.38
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ GKOS ] has closed below upper band by 47.4%. Bollinger Bands are 43.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 109.88 - 110.61 110.61 - 111.26
Low: 105.47 - 106.4 106.4 - 107.25
Close: 107.45 - 108.92 108.92 - 110.24
Company Description

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

Headline News

Mon, 27 May 2024
Aigen Investment Management LP Invests $228000 in Glaukos Co. (NYSE:GKOS) - Defense World

Sun, 26 May 2024
Neuberger Berman Group LLC Raises Holdings in Glaukos Co. (NYSE:GKOS) - MarketBeat

Sun, 26 May 2024
Glaukos Co. (NYSE:GKOS) Shares Acquired by Trexquant Investment LP - Defense World

Sun, 26 May 2024
Quadrant Capital Group LLC Acquires 329 Shares of Glaukos Co. (NYSE:GKOS) - Defense World

Fri, 24 May 2024
Zacks Research Research Analysts Lower Earnings Estimates for Glaukos Co. (NYSE:GKOS) - MarketBeat

Fri, 24 May 2024
Here's Why Glaukos Corporation's (NYSE:GKOS) CEO Compensation Is The Least Of Shareholders' Concerns - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Medical - Devices
Shares Out 50 (M)
Shares Float 49 (M)
Held by Insiders 3.4 (%)
Held by Institutions 104.7 (%)
Shares Short 3,510 (K)
Shares Short P.Month 3,490 (K)
Stock Financials
EPS -2.89
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 9.03
Profit Margin -43.2 %
Operating Margin -32 %
Return on Assets (ttm) -8 %
Return on Equity (ttm) -29.4 %
Qtrly Rev. Growth 15.8 %
Gross Profit (p.s.) 0
Sales Per Share 6.48
EBITDA (p.s.) -1.73
Qtrly Earnings Growth 0 %
Operating Cash Flow -61 (M)
Levered Free Cash Flow -23 (M)
Stock Valuations
PE Ratio -37.81
PEG Ratio -6.1
Price to Book value 12.04
Price to Sales 16.8
Price to Cash Flow -90.13
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android